Related Experiment Videos
Clarithromycin for Helicobacter pylori infection.
1Department of Medicine & Therapeutics, Prince of Wales Hospital, Shatin, Hong Kong SARA.
Expert Opinion on Pharmacotherapy
|March 16, 2001
Summary
Helicobacter pylori (H. pylori) infection treatment has evolved, with clarithromycin-based therapies showing high success rates in susceptible patients. However, increasing antibiotic resistance necessitates improved therapeutic strategies.
Area of Science:
- Microbiology
- Gastroenterology
- Pharmacology
Background:
- Helicobacter pylori (H. pylori) is a common Gram-negative bacterium infecting up to half the US population.
- Chronic H. pylori infection is linked to gastritis, peptic ulcers, and gastric cancer.
- Effective eradication of H. pylori promotes healing and prevents ulcer recurrence.
Purpose of the Study:
- To review the evolution and current state of H. pylori treatment.
- To highlight the efficacy and limitations of clarithromycin-containing regimens.
- To underscore the need for novel therapies addressing antibiotic resistance.
Main Methods:
- Review of current H. pylori treatment guidelines and antimicrobial efficacy.
- Analysis of clarithromycin's role, including its mechanism and resistance patterns.
- Evaluation of standard triple and quadruple therapies.
Main Results:
- Proton pump inhibitor (PPI)-based triple or quadruple therapies are current standards.
- Clarithromycin offers high efficacy against susceptible H. pylori strains when combined with PPIs and other antibiotics.
- Increasing clarithromycin resistance, due to 23S rRNA mutations, significantly reduces treatment success.
Conclusions:
- While clarithromycin-based therapies can achieve >95% eradication rates in susceptible H. pylori infections, rising resistance is a major concern.
- The emergence of clarithromycin resistance necessitates the development of alternative treatment strategies.
- Improved therapies are crucial for overcoming antibiotic resistance challenges in H. pylori eradication.